11/01/2025
Less than 1 mg of THC and CBD each a day significantly improved performance on a cognition test…
“A Phase 2, randomized, double-blind, placebo-controlled, clinical trial including patients between 60 and 80 years-old diagnosed with AD-associated dementia. For 26 weeks, participants orally received either placebo or THC-CBD extract (0.350 mg/THC and 0.245 mg/CBD), daily.
Results
At week 26, Mini-Mental State Exam total score was significantly higher in cannabis- when compared to placebo-treated patients…”
Clinical trial data published in the Journal of Alzheimer’s Disease